UroGen Pharma Ltd (URGN)
Healthcare
Biotechnology
38.20 $
-6.9%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns UroGen Pharma Ltd (URGN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 88.6% of the shares are freely tradable; institutional investors hold 100.6%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
100.6%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
3.6%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
88.6%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
13.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
49Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| RTW INVESTMENTS, LLC | 9.33 | 4,543,895 | +0.0 | 03/31/2026 |
| BlackRock Inc | 5.84 | 2,845,567 | +9.4 | 03/31/2026 |
| The Toronto-Dominion Bank | 5.37 | 2,616,714 | +0.0 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 5.25 | 2,560,038 | -0.1 | 03/31/2026 |
| Kynam Capital Management, LP | 4.61 | 2,247,393 | +0.0 | 03/31/2026 |
| Jefferies Financial Group Inc | 4.51 | 2,199,652 | +0.0 | 03/31/2026 |
| Paradigm Biocapital Advisors LP | 3.50 | 1,703,949 | -61.9 | 03/31/2026 |
| SG Americas Securities, LLC | 3.40 | 1,657,846 | +20.3 | 03/31/2026 |
| American Century Companies Inc | 3.36 | 1,637,570 | +20.5 | 03/31/2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 3.09 | 1,503,045 | -13.6 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.